What is Relmada Therapeutics, Inc.'s share buybacks?

Relmada Therapeutics, Inc. (RLMD) reported share buybacks of $3.36M in Q1 2026.

What does share buybacks mean?

Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.

Johnson & JohnsonJNJ

$4.03B+89.4%

Merck & Co.MRK

$874M-24.9%

Rigel PharmaceuticalsRIGL

$3.74M—

Neuropace, Inc.NPCE

$0-100%

Eli LillyLLY

$2.36B+96.3%

Operating income-$19.5M-6.8%

Net income-$19.1M-8.5%

EPS (diluted)-$0.22+62.1%

Cash & equivalents$9.8M+750%

Total debt$104.1M-40.4%

Total equity$218.7M+875%

Total assets$235.4M+750%

Operating cash flow-$15.1M+16.6%

Market cap$677.17M+2,907%

Return on equity-48.8%-20.0pp

Debt / equity0.9×0.0×

Current ratio18.3×+13.0×

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Relmada Therapeutics, Inc.'s share buybacks?: Relmada Therapeutics, Inc. (RLMD) reported share buybacks of $3.36M in Q1 2026.
What does share buybacks mean?: Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.